A clinical trial update relevant to terlipressin was recorded on September 9, 2026. The study, titled "Using Bedside Ultrasound to Understand Fluid Management in Patients With Chronic Liver Disease," carries the identifier NCT07810855. Its current status is listed as not yet recruiting. No phase information was provided for this trial in the available record.
Terlipressin remains an approved compound, and this listing reflects an administrative update in the trial registry rather than any new clinical result. No outcomes, efficacy data, or safety findings have been reported as part of this update. The trial's focus, as named, involves bedside ultrasound methods to understand fluid management in patients with chronic liver disease, a population in which terlipressin is used.
Because the study has not yet begun recruiting participants, no enrollment, interim, or results data currently exist. Readers should treat this as an early registration milestone only. Future updates may provide additional details as the trial status changes, including anticipated recruitment timelines or design specifics not yet disclosed in this record.
For more background on this compound, readers can consult the compound overview.